好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Digital Speech Assessments in Huntington Disease
General Neurology
S43 - General Neurology 2 (2:48 PM-3:00 PM)
010

To explore the potential of speech data as a digital measure in assessing the progression of Huntington disease (HD) and its clinical implications.
Speech changes are an early symptom of Huntington disease (HD) and may occur prior to other motor and cognitive symptoms. Traditional HD assessments utilize clinician-rated outcome measures. These can be limited by observer variability and episodic administration. Digital assessment of speech can provide a quantitative evaluation apt for frequent and remote administration.
Recordings of 33 participants (15 HD, 7 prodromal HD, and 11 control) were collected while reading a passage speech task. Biodigit Speech was used to analyze the recording and extract speech features such as pausing, pitch, and intelligibility. The features were compared between HD, prodromal HD and controls, and also correlated with the Unified Huntington Disease Rating Scale (UHDRS) subscales. Machine learning models based on random forest algorithms were employed to predict clinical status and scores from speech features.
Observable differences in pausing, intelligibility, and accuracy for passage reading among the HD, prodromal HD, and control groups were identified. The random forest classifier correctly predicted the three clinical status from speech tasks with an accuracy rate of 73%. Random forest regression predicted UHDRS clinical scores from speech features with explained variance between 14% and 54%.
Speech data presents a great potential as a key digital measure in monitoring neurodegenerative progression. It can facilitate remote, regular assessments of the disease in prodromal HD and HD stages. Through the extracted speech features, random forest machine learning models adeptly predicted clinical status and disease severity. This suggests that speech measurements might be a sensitive marker for determining clinical onset and progression in upcoming clinical trials.
Authors/Disclosures
Ashkan Vaziri, PhD (Biosensics LLC)
PRESENTER 		Dr. Vaziri has received personal compensation for serving as an employee of Biosensics.
Adonay Nunes (Biosensics) Adonay Nunes has nothing to disclose.
Meghan E. Pawlik, MS (Center for Health + Technology) Miss Pawlik has nothing to disclose.
Ram Kinker Mishra (Biosensics) Ram Kinker Mishra has received personal compensation for serving as an employee of BioSensics LLC.
E. Ray Dorsey, MD, MBA (University of Rochester) Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seelos Therapeutics. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eden McCallum, LLP. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/Roche. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Dorsey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioSensics. Dr. Dorsey has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Mediflix. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevance. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kairos Cinema, LLC. Dr. Dorsey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America Inc.. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medrhythms. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ANA. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for HMP 好色先生, LLP. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ADIVO Associates France. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for University of Toronto. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philadelphia Neurological Society. Dr. Dorsey has stock in Included Health. Dr. Dorsey has stock in Mediflix. Dr. Dorsey has stock in SemCap. Dr. Dorsey has stock in Synapticure. The institution of Dr. Dorsey has received research support from NIH/NINDS. The institution of Dr. Dorsey has received research support from Burroughs Wellcome . The institution of Dr. Dorsey has received research support from Michael J. Fox Foundation - Fox Insight. The institution of Dr. Dorsey has received research support from Michael J. Fox Foundation - Emerald. The institution of Dr. Dorsey has received research support from B. Thomas Golisano Foundation. The institution of Dr. Dorsey has received research support from Emerald Innovations, Inc.. The institution of Dr. Dorsey has received research support from Photopharmics Inc.. The institution of Dr. Dorsey has received research support from Averitas Pharma Inc.. The institution of Dr. Dorsey has received research support from DOD/Army Medical Research Acquisition Activity. The institution of Dr. Dorsey has received research support from NIH/NINDS.
Jamie L. Adams, MD (University of Rochester Medical Center) Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Adams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Adams has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioSensics. The institution of Dr. Adams has received research support from NIH/NINDS. The institution of Dr. Adams has received research support from Biogen. The institution of Dr. Adams has received research support from The Michael J. Fox Foundation. The institution of Dr. Adams has received research support from Critical Path Institute. Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a KINECT-HD Steering Committee Member with Huntington Study Group. Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a ORCHESTRA-PD Steering Committee Member with Parkinson Study Group.